ID
45778
Description
Principal Investigator: Elaine A Ostrander, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001105 We collected DNA from fresh frozen prostate tumor samples and matched peripheral blood from 10 subjects with aggressive, Gleason score ≥8 disease. Tumor and normal samples were sequenced on the Illumina HiSeq 2000 to mean depths of 95.3X and 48.3X, respectively.
Link
Keywords
Versions (1)
- 6/20/23 6/20/23 - Chiara Middel
Copyright Holder
Elaine A Ostrander, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Uploaded on
June 20, 2023
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs001105 NHGRI-Mayo Clinic Whole Genome Sequencing of Aggressive Prostate Tumors
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for prostate tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, family history of prostate cancer, ages at diagnosis and at surgery, prostate specific antigen (PSA) at diagnosis, treatment prior to surgey, lymphadenectomy, pathology Gleason score, pathology primary and secondary Gleason grades, total number of lymph nodes examined, number of positive lymph nodes, and estimated tumor volume (cc).
- This sample attributes table contains sample IDs, analyte type, body site where sample was collected, tumor status, primary metastatic tumor, primary tumor location, DNA isolation method, sequencing platform, chemistry version, and name of the center which conducted genotyping.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for prostate tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, family history of prostate cancer, ages at diagnosis and at surgery, prostate specific antigen (PSA) at diagnosis, treatment prior to surgey, lymphadenectomy, pathology Gleason score, pathology primary and secondary Gleason grades, total number of lymph nodes examined, number of positive lymph nodes, and estimated tumor volume (cc).
- This sample attributes table contains sample IDs, analyte type, body site where sample was collected, tumor status, primary metastatic tumor, primary tumor location, DNA isolation method, sequencing platform, chemistry version, and name of the center which conducted genotyping.
C0680251 (UMLS CUI [1,2])
C3203027 (UMLS CUI [1,2])
C0470187 (UMLS CUI [1,3])
C4697670 (UMLS CUI [1,4])
C0033573 (UMLS CUI [1,5])
C1292533 (UMLS CUI [1,6])
C0229664 (UMLS CUI [1,7])
C0012854 (UMLS CUI [1,8])